Alexion/P&G Pexelizumab Failed Phase III Could Compromise Partnership
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A development partnership between Alexion and Procter & Gamble could be called into question following negative results of two Phase III trials of the terminal complement inhibitor pexelizumab
You may also be interested in...
Alexion Eyes Thrombosis Market For Next Soliris Patient Identification Push
Alexion is considering running a new program in the thrombosis market to identify potential paroxysmal nocturnal hemoglobinuria patients for Soliris, along the lines of the firm's ongoing EXPLORE diagnostics program looking for PNH in the bone marrow failure setting
Alexion pexelizumab fails second PRIMO study
Alexion's terminal complement inhibitor pexelizumab fails to show statistical significance in the firm's second coronary artery bypass graft trial, PRIMO-CABG2. Alexion is assessing the implications of the results on its APEX-AMI study of the biologic in acute myocardial infarction. When pexelizumab failed the first PRIMO (Pexelizumab for Reduction in Infarction & Mortality) study in August 2003, Alexion said the results could be used to support an AMI indication (Pharmaceutical Approvals Monthly September 2003, p. 21). The APEX study has enrolled 3,000 patients, according to the firm...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011